Investigating the Nexus between Gynaecologic Cancer and Human Development Index

Ruqiya Pervaiz, Faisal Faisal


This study aimed to describe the current incidence and mortality rates of gynecologic cancer and their association with socio-economic development. The data for the age-standardized incidence rate (ASRI) and age-standardized mortality rate (ASRM) were acquired from the GLOBOCAN-2012 database. Human Development Index (HDI) data were obtained from the 2015-Human Development Report. The correlation between HDI and Mortality to Incidence Ratio (MIR) was assessed by Pearson-correlation. The effect of national-HDI on MIR was analyzed by linear regression analysis. The ASRI, ASRM, and MIR of cervix cancer were higher in the less developed regions (LDRs) than in more developed regions (MDRs). However, for corpus uteri cancer, the ASRI was 3.6 times and the ASRM was 1.5-times higher in the MDRs than in the LDRs. Strong inverse associations between MIR and HDI were reported from cervix (adjusted R2 = 0.825, β = – 0.908, p < 0.001), corpus uteri (adjusted R2 = 0.554, β = – 0.746, p < 0.001) and ovarian cancer (adjusted R2 = 0.579, β = – 0.763, p < 0.001). The higher MIR of gynecologic cancer in LDRs demand for sustainable investment in health systems and balanced cancer control plans in the region. (Afr J Reprod Health 2020; 24[1]: 53-61).

Full Text:



Stewart BW and Wild CP, editors. World Cancer Report

International Agency for Research on Cancer (IARC) 2014.

Mokarian F, Ramezani MA, Heydari K, Tabatabaeian M

and Tavazohi H. Epidemiology and trend of cancer in Isfahan 2005-2010. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences 2011; 16 (9): 1228-1233.

Luengo-Fernandez R, Leal J, Gray A and Sullivan R.

Economic burden of cancer across the European Union: a population-based cost analysis. The Lancet Oncology 2013; 14 (12):1165-1174.

Jemal A, Center MM, DeSantis C and Ward EM. Global

patterns of cancer incidence and mortality rates and trends, Cancer Epidemiology and Prevention Biomarkers 2010; 19 (8): 1893-1907. doi. 10.1158/1055-9965.EPI-10-0437

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ and Brown

ML. Projections of the cost of cancer care in the United States: 2010–2020. Journal of the National Cancer Institute 2011; 103 (2): 117-128.

Sankaranarayanan R and Ferlay J. Worldwide burden of

gynecological cancer: the size of the problem. Best Practice & Research Clinical Obstetrics & Gynecology 2006; 20 (2): 207-225. org/10.1016/j.bpobgyn.2005.10.007.

Pervaiz R and Faisal F. Cancer incidence and mortality

are associated with human development index and health setups in Africa. Journal of the Egyptian National Cancer Institute 2017; 29 (3): 123-126.

International Agency for Research on Cancer (2012)

GLOBACAN 2012: Cancer Incidence, Mortality and Prevalence Worldwide in 2012. JARC. [Accessed on 01-08-2017].

Choi E, Lee S, Nhung BC, Suh M, Park B, Jun JK and

Choi KS. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. Epidemiology and Health 2017; 39. doi: 10.4178/epih.e2017006.

Programme UND. Work for Human Development. Human Development Report 2015.

United Nation Population Division Unit. Department of

Economic and Social Affairs. World Population Prospects: The 2017 Revision. Classification of countries by region, income group and sub region of the world. [Accessed on 01-08-2017]

Engle RF. Autoregressive conditional heteroscedasticity

with estimates of the variance of United Kingdom inflation. Econometrica: Journal of the Econometric Society 1982: 987-1007.

Breusch TS and Pagan AR. The Lagrange Multiplier Test

and its Application to Model Specification in Econometrics. Review of Economic Studies 1980; 47 (1), 239–253.

Jarque CM and Bera AK. A test for normality of

observations and regression residuals. International Statistical Review/Revue Internationale de Statistique, 1987; 163-172.

Pinneau SR, Levine AJ, Schurr BC and Butler DC. Analysis of factor variance: one-way classification. Perceptual and Motor Skills 1966; 23 (3_suppl): 1209-1210.

Sharma V, Kerr SH, Kawar Z and Kerr DJ. Challenges of

cancer control in developing countries: current status and future perspective. Future Oncology 2011; 7 (10): 1213-1222.

Pervaiz R, Tulay P, Faisal F and Serakinci N, Incidence

of cancer in the Turkish Republic of Northern Cyprus, Turkish Journal of Medical Sciences 2017; 47 (2): 523-530. doi:10.3906/sag-1510-145.

World Health Organization. Cancer control: a global

snapshot in 2015. WHO NCD Country Capacity Survey. World Health Organization; 2015. [Accessed on 01-08-2017]

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C,

Rebelo M, Parkin DM, Forman D and Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015; 136 (5): E359-386.

Mathew A and George PS, Trends in incidence and

mortality rates of squamous cell carcinoma and adenocarcinoma of cervix–worldwide, Asian Pacific Journal of Cancer Prevention 2009; 10 (4): 645-650.

Sherris J, Wittet S, Kleine A, Sellors J, Luciani S, Sankaranarayanan R and Barone MA. Evidence-based, alternative cervical cancer screening approaches in low-resource settings, International Perspectives on Sexual and Reproductive Health 2009; 35 (3): 147-152.

Harper DM and DeMars LR. HPV vaccines– A decade in

review. Gynecologic Oncology Reports 2017; 22: 115-116. doi: 10.1016/j.gore.2017.11.008.

Ries LA, Young Jr JL, Keel GE, Eisner MP, Lin YD and

Horner MJ. Cancer survival among adults: US SEER program, 1988–2001. Patient and Tumor Characteristics SEER Survival Monograph Publication 2007. 07-6215.

Schottenfeld D and Fraumeni JF Jr, editors. Cancer

Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006.

El Mistiri M, Salati M, Marcheselli L, Attia A, Habil S,

Alhomri F, Spika D, Allemani C and Federico M. Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry. Annals of Epidemiology 2015; 25 (8): 564-568.

De Angelis R, Sant M, Coleman MP, Francisci S, Baili P,

Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E and Bielska-Lasota M. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. The Lancet Oncology 2014; 15 (1): 23-34.

Boyle P and Levin B. World cancer report 2008. International agency for research on cancer. Distributed by WHO Press, Lyon/Geneva. 2008.

Ingerslev K, Hogdall E, Schnack TH, Skovrider-Ruminski W, Hogdall C and Blaakaer J. The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. Infectious Agents and Cancer 2017; 12 (1): 25.

Agarwal G, Ramakant P, Forgach ER, Rendón JC, Chaparro JM, Basurto CS and Margaritoni M Breast cancer care in developing countries. World Journal of Surgery 2009; 33 (10): 2069.

Collingridge D, Three countries—half of the global cancer burden. The Lancet Oncology 2014; 15 (5): 483.

Camp SL. Population pressure, poverty and the environment. Integration (Tokyo, Japan) 1992; (32): 24.

Bray F, Znaor A, Cueva P, Korir A, Swaminathan R,

Ullrich A, Wang SA and Parkin DM. Planning and developing population-based cancer registration in low-and middle-income settings. IARC (International Agency for Research on Cancer) Technical Report No. 43, 2014.


  • There are currently no refbacks.